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Abstract 10 
Currently, cryo-banking of multicellular structures such as organoids, especially in large 11 
volumes at clinical scale >1 litre , and large volumes remains elusive for reasons such as 12 
insufficient dehydration and cryoprotectant additive (CPA
1
) penetration, slow cooling and 13 
warming rates and devitrification processes. Here we introduce the concept of Liquidus 14 
Tracking (LT) using a semi-automated device for liquid volumes of up to 450ml including  15 
130ml of alginate encapsulated liver cells (AELC) that archived controlled and reversible 16 
vitrification with minimized toxicity. 17 
First a CPA solution with optimal properties for LT was developed by employing different 18 
small scale test systems. Combining sugars such as glucose and raffinose with Me2SO 19 
improved post-exposure (at +0.5˚C) viabilities from 6 +/- 3.6% for Me2SO alone up to 58 +/- 20 
6.1% and 65+/-14.2 % respectively (p<0.01). Other permeating CPAs (e.g. ethylene glycol, 21 
propylene glycol, methanol) were investigated as partial replacements for Me2SO. A mixture 22 
                                                 
1
 cryoprotectant additive (CPA), Liquidus Tracking (LT), alginate encapsulated liver cells 
(AELC), alpha-fetoprotein (AFP), mixture of Me2SO, ethylene glycol and glucose (ratio 
4:2:1): termed LTdeg. 
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of Me2SO, ethylene glycol and glucose (ratio 4:2:1– termed LTdeg) supported glass-forming 23 
tendencies with appropriate low viscosities and toxicities required for LT. When running the 24 
full LT process, using Me2SO alone, no viable cells were recovered; using LTdeg, viable 25 
recoveries were improved to 40+/-8% (p<0.001%). Further refinements of improved mixing 26 
technique further improved recovery after LT. Recoveries of specific liver cell functions such 27 
as synthesis of albumin and alpha-fetoprotein (AFP) were retained in post thaw cultures. 28 
In summary: By developing a low-toxicity CPA solution of low viscosity (LTdeg) suitable 29 
for LT and by improving the stirring system, post-warming viability of AELC of up to 90% 30 
and a AFP secretion of 89% were reached. Results show that it may be possible to develop 31 
LT as a suitable cryogenic preservation process for different cell therapy products at large 32 
scale. 33 
Keywords 34 
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Introduction 36 
Scientists have successfully cryopreserved a variety of cells over the last 40 years, but success 37 
has mainly been achieved by traditional slow cooling with cell suspensions in small (<10 ml) 38 
volumes [16,45] in tube format, or in bag format in volumes of up to 200ml [10,17,33]. 39 
Cooling multicellular systems down to deep sub-zero temperatures has proven far more 40 
challenging, especially when large volumes of biomass require cryo-banking. These problems 41 
began to be understood during early attempts to cryopreserve whole organs or large complex 42 
tissues. They were mainly related to the formation of extracellular ice in liquid spaces within 43 
the tissue [37], such as within small capillary blood vessels inside an organ [19], which 44 
physically destroyed the internal structure. In addition,  disruptive ice propagation between 45 
inter-connected cells [1], insufficient cell dehydration and CPA penetration during slow 46 
cooling and ice-recrystallization during the warming process have all been noted. These can 47 
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also make cell agglomerates more susceptible to freezing damage than individual cells. Ice 48 
formation can be avoided by vitrification, but high cooling rates must frequently be imposed 49 
to avoid toxic effects from the essentially high CPA concentrations required and to maximise 50 
the likelihood of achieving the glassy state without ice nucleation events [13]. This remains a 51 
significant challenge for large tissues or, equally, for large volumes of functionally 52 
interconnected cells such as cell spheroids, as enough time must be given for CPA to 53 
penetrate into the all the cells, including those in the core, and for the core cells to dehydrate 54 
sufficiently to avoid intracellular freezing, risking toxic effects during CPA exposure and 55 
cooling. CPA toxicity is also critical during the warming process when high concentrations of 56 
CPAs will be present when the cryogenic glasses begin to liquefy; equally the high warming 57 
rates needed to prevent devitrification and ice re-crystallisation for all cells within a sample 58 
are difficult to achieve in large volumes [6,7]. 59 
Many of those obstacles can be overcome by Liquidus Tracking (LT), a method of achieving 60 
vitrification in an aqueous mixture by incrementally increasing concentrations of penetrating 61 
CPAs (up to 70%) at incrementally decreasing temperatures [15,38,47]. Cryoprotectants are 62 
known to be less toxic at lower concentrations, but also at lower temperatures [34,48] due to 63 
decreased cell activity, reduced chemical interaction with sensitive biomolecules  and 64 
reduced CPA permeation. Due to reduced CPA toxicity, and avoidance of ice nucleation in 65 
LT, large samples can be vitrified without the necessity of fast cooling rates, or when longer 66 
exposure times are required to allow for sufficient CPA penetration - for example for organ 67 
and tissue vitrification. 68 
We have previously studied cryopreservation by slow cooling of alginate encapsulated 69 
multicellular liver cell spheroids (AELC) in developing a bioartifical liver support system 70 
[31]. Treatment volumes of between 1-2 litres of AELC for use in a bioartificial liver device 71 
have been used in our pre-clinical studies [11] and are predicted to be needed for patient 72 
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therapy. We have also shown that LT vitrification can be applied to AELC in a small volume 73 
feasibility study [40]. Our aim here was to develop a LT protocol, which would allow the 74 
cryo-banking and warming of large volumes of AELC whilst maintaining good functional 75 
recovery. To improve cell viability we have developed a low-toxicity CPA solution for LT 76 
with the requirement of low viscosity (but which – nevertheless – could suppress ice 77 
nucleation) so that it may be used within the Liquidus Tracker equipment. Additionally the 78 
development of a new stirring system substantially increased post-warming viability. 79 
Materials and Methods 80 
Unless otherwise stated, all chemicals were sourced from Sigma (Poole, United Kingdom) 81 
and for cooling and warming a PlanerLiquidus Tracker Controller and a Controlled Rate 82 
Freezer (Planer, Kryo 10, Series II chamber) was used. CPA concentrations were used and 83 
reported in weight per volume (w/v) throughout this work. 84 
Cell culture and encapsulation 85 
The techniques for culturing HepG2 cells and producing AELC have been described 86 
previously in detail [11]. In brief: Confluent HepG2 monolayer cells (from ECACC, 87 
Wiltshire, UK) were encapsulated into 1% alginate (alginic acid sodium salt Macrocystis 88 
pyrifera kelp) by calcium-related polymerisation and cultured for >11 days until containing 89 
several thousand cells in spheroids within each alginate bead (average diameter 450µm). 90 
Cell culture to different end cell densities 91 
For experiments that required different cell densities, AELC were cultured for either 3, 5, 7, 9 92 
or 11 days before being used for LT. 93 
Viability assay 94 
Cell viability was measured by dual staining with fluorescein diacetate and propidium iodide 95 
using an established imaging software method for quantification which has been established 96 
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against cell number and protein production [21]. Viability was measured after 24 hours post-97 
treatment, the time point of lowest viability before on-set of recovery [31]. 98 
Quantification of cell numbers  99 
Cell number quantification using the Nucleoview System (Sartorius Stedim, Epsom, United 100 
Kingdom) has been described previously in detail [11]. Viable cell numbers were calculated 101 
by multiplying the cell number by the viability for each sample. 102 
Functional assays to assess protein synthesis by alpha-fetoprotein and albumin secretion 103 
Alpha-fetoprotein (AFP) and albumin synthesis and secretion  were measured by sandwich 104 
enzyme-linked immunosorbent assay which has been described previously in detail [11]. 105 
Viscosity assessment and measurement 106 
Viscosity of CPA mixtures is an important factor in applying LT to facilitate good mixing 107 
and ensure uniform high CPA concentrations to avoid ice nucleation. Viscosity of CPA 108 
solutions was assessed for applicability by comparing new CPA solutions against a reference 109 
solution (70% (w/v) Me2SO) by observational grading of resistance  to pipetting or to 110 
manually stirring the solution at -40˚C  –  the lowest workable LT  temperature from previous 111 
experience [40]. For pipetting a standard 1ml Eppendorf pipette and 1ml pipette tips and for 112 
stirring a stainless steel spatula with a 4mm width were used. 10ml CPA in 15ml Centrifuge 113 
tubes (Falcon, Fisher Scientific) were cooled to -40˚C. This test was developed as no 114 
viscometers or rheometers operable at -40˚C were available locally and it also allowed direct 115 
rapid assessment of multiple samples. Viscosity was rated 1-4 (1 = similar to 70% (w/v) 116 
Me2SO, easy to pipette; 2 = pipetting not possible but can be easily stirred, 3 = very viscous, 117 
stirring very difficult, 4 = stirring not possible, almost a solid). Solutions with a viscosity 118 
rating of “2” were modified by replacing 10% of the highly viscous CPAs with less viscous 119 
CPAs. In particular methanol was selected as a low viscosity CPA to reduce the overall 120 
viscosity of the mixture. Thereafter, viscosities of the most promising CPA solutions were 121 
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measured at 20˚C using a Bohlin CVO automated shear rheometer to provide a set of 122 
reference data. Shear stress (s
-1
) was increased by 10rpm every 10 seconds, from 10 to 123 
250rpm.  124 
CPA toxicity tests 125 
A two-step protocol was used to reduce potential CPA-related osmotic injury based on 126 
previous experience with AELC which have shown high viabilities after one step addition 127 
and dilution of up to 40% Me2SO (v/v) [40]. A volume of 0.25ml settled beads (AELC) was 128 
incubated in a 30% (w/v) CPA solution for five minutes at room temperature (Falcon tubes, 129 
Fisher Scientific), then for five minutes at 0.5˚C (tubes in ice-water). The concentration was 130 
then increased to 60% (w/v) CPA and beads incubated for 10 or 20 minutes at 0.5˚C. CPA 131 
concentration and incubation time were chosen to display strong difference in survival 132 
between solutions. By adding 1xPBS for dilution steps, the CPA concentration was reduced 133 
to 30% (w/v). Samples were left on ice for five minutes. Beads were washed twice with 4ml 134 
of 1xPBS and incubated in complete medium for 24 hours before viability was assessed. 135 
Optical vitrification assessment 136 
A volume of 4ml of each newly developed CPA solution and Me2SO at a concentration of 137 
60% and 70% (w/v) was vitrified in a 12-well plate by cooling samples at -10 ̊C/min to -138 
160 ̊C. All solutions were then left at room temperature for warming and optical observation. 139 
Standard small volume vitrification protocol 140 
A traditional two-step small volume protocol was used to assess vitrification of AELC per se 141 
and allow comparison to LT. Therefore 0.25ml settled beads were incubated in a 31.5% (w/v) 142 
CPA solution in Nunc cryo-tubes (1.8 ml, Nunc, Loughborough, UK), first for five minutes at 143 
room temperature and then for an additional five minutes at 0.5˚C (tubes in ice-water). The 144 
CPA concentration was increased to 63% (w/v) using a 70% (w/v) pre-cooled CPA solution 145 
(at 0.5˚C). Samples were left on ice for five minutes and then plunged into liquid nitrogen. 146 
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Samples were warmed for approximately eight minutes on ice until they reached a liquid 147 
state. By adding ice cold 1xPBS (+Mg
2+
, Ca
2+
) the CPA concentration was reduced to 31.5% 148 
(w/v). Samples were left on ice for five minutes before washing twice with 4ml 1xPBS 149 
(+Mg
2+
, Ca
2+
). Finally, AELC were incubated in complete media for 24 hours before 150 
assessing viability. 151 
Liquidus Tracking 152 
The prototype Planer LT machine consists of a sample carrier with a magnetic stirrer which is 153 
placed inside a Controlled Rate Freezer (Planer, Kryo 10, Series II chamber) and an inlet and 154 
outlet pump system [40]. All of these units are connected to a controller, which allows a 155 
completly automated cooling, mixing and addition and extraction process when using a single 156 
highly concentrated CPA solution. For the work presented here the peristaltic pumps were 157 
operated manually to allow for the use of differently concentrated CPA inlet solutions for 158 
both the cooling and warming process. A liquid volume of 450ml including 130ml of settled 159 
beads was used for each run, if not stated otherwise. 160 
(i) LT cooling: The controlled rate freezer was first set on hold at -20˚C and then -25˚C until 161 
the sample reached a concentration of 32% (w/v) at -12˚C and 40% (w/v) at -16˚C, 162 
respectively, by pumping in a 50% CPA inlet solution. After that the freezer was set to -163 
30˚C and a 60% (w/v) CPA solution was used to increase the sample to 50% (w/v) (at -164 
20˚C) and subsequently a 66% (w/v) CPA solution was added to reach a final sample 165 
concentration of 64% (w/v) (at -20˚C). CPA increase to 25% (w/v) were carried out by 166 
addition only, increase to 64% (w/v) was reached by operating both inlet and outlet 167 
pump simultaneously at a flow rate of 20ml/min. Then the freezer was set to -160˚C to 168 
cool the sample below the predicted glass transition temperature of about -121˚C. 169 
Samples were held for a minimum of 10 minutes below -125˚C (Figure 2). The 170 
temperature was measured in the middle of the sample carrier, where cooling is slowest. 171 
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(ii) LT warming: The sample carrier remained inside the freezer but with the liquid nitrogen 172 
supply shut off for slow warming to -95˚C. For fast warming to -40˚C the sample carrier 173 
was placed outside the freezer at room temperature. For LT reversed warming, first 174 
500ml of a 50%, then a 40% and then a 30% (w/v) CPA solution were pumped in at 175 
20ml/min to decrease the sample CPA concentration. Simultaneously sample solution 176 
was extracted at 20ml/min. The freezer holding temperature was increased from initially 177 
-25˚C to -20˚C and then -15˚C for 30 minutes. Finally, the freezer was set to -10˚C and 178 
1L 1xPBS (at 20˚C) was added to decrease the sample CPA concentration to 0% (Figure 179 
2).  180 
The temperature-concentration curve 181 
For each LT run the temperature/concentration (T/C) curve was determined by measuring the 182 
CPA concentration of the chamber outlet solution and by correlating this value to the sample 183 
temperature reached at the end of the extraction cycle. Thermocouples inserted into the inlet 184 
and outlet tube and inside the sample carrier were used to monitor the temperature. The 185 
refractive index (Digital Refractometer, Cole-Pamer Brix, 45.0 to 95.0%, EW-02941-33) was 186 
used to determine the CPA concentration of the outlet solution based on a previously 187 
established standard curve [40]. 188 
Filter system 189 
To maintain AELC beads (average diameter (d) =450µm) inside the sample carrier during 190 
CPA extraction and to avoid filter blockage, a plastic tube (5cm length, d=4cm) was covered 191 
from both ends with a 100µm mesh through which the outlet port was introduced. The filter 192 
was placed 1cm away from the opening of the port – where the suction force was highest – to 193 
avoid the filter getting blocked by beads. 194 
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Avoiding devitrification 195 
To ensure that devitrification during warming was avoided, a finally sample CPA 196 
concentration of 64% (w/v) had to be reached, before the fast cooling process to below -197 
121˚C was started. 198 
Differential scanning calorimetry 199 
To establish the liquidus curve of the newly developed CPA solution, differential scanning 200 
calorimetry (DSC) was used to determine the equilibrium melting point of increasing CPA 201 
concentrations. The method has been described previously in detail [32].  202 
Statistics 203 
Statistical analyses were performed by Student's t-Test using Excel software. 204 
Results 205 
CPA development 206 
(i) Viscosity - candidate CPA combinations 207 
It was predicted that at least 40% (w/v) penetrating CPAs and a maximum total concentration 208 
of 70% (w/v) CPA should be used to obtain sufficient vitrification for large volumes and 209 
slow cooling rates (<10˚C/min) from previous feasibility studies [40]. By using the 210 
observational viscosity test at -40˚C only four solutions were identified with a similar 211 
viscosity to 70% (w/v) Me2SO when comparing (in increments of 10%) combinations of 212 
Me2SO, EG and PG with the non-penetrating CPA glucose. All of these solutions contained 213 
at least 40% (w/v) Me2SO, but only 10% (w/v) glucose. The viscosity of another eight 214 
solutions was sufficiently reduced for Liquidus Tracking through the substitution of 10% 215 
(w/v) of a penetrating CPA with methanol (Figure 1).  Viscosity of CPA solutions of lowest 216 
toxicity were additionally measured with a Bohlin® CVO automated shear rheometer at 20˚C 217 
displaying lowest viscosity for 70% (w/v) Me2SO with 4.62mPa·s and highest viscosity for 218 
40% Me2SO with 20% EG and 10% glucose (w/v) with 6.51mPa·s (Table 1). 219 
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(ii) Testing different sugars and sugar combinations 220 
To improve post-warming LT cell survival, non-penetrating sugars were added to Me2SO, 221 
which yielded poor AELC viability when used as a single CPA. Viability of AELC, 222 
incubated in 50% (w/v) Me2SO, decreased from 90% +/- 2.15 (n=5) to 5.9% +/-3.6 (n=5). 223 
The addition of 10% (w/v) of any sugar (glucose, fructose, raffinose, sucrose, trehalose) 224 
increased cell viability markedly by up to 50% although the final CPA concentration was 225 
increased to 60% (w/v). The combination of glucose with another sugar (5% (w/v) each) did 226 
not significantly increase cell viability (Figure 3).  227 
(iii) Toxicities of low viscous CPA solutions 228 
Glucose was chosen as a CPA additive because it is readily available in large quantities, 229 
inexpensive and is clinically used. In a pre-screening toxicity test, solutions containing 230 
methanol (10% w/v) were generally more toxic to AELC than those without. Methanol was 231 
only well tolerated when the Me2SO concentration was equal or less than 30% (w/v) and with 232 
at least 10% (w/v) EG. The toxicity test was repeated in more replicates with the five most 233 
promising solutions. Additionally, these solutions were used to vitrify AELC in a standard 234 
small volume approach (Table 1, Figure 1). Both tests revealed the same order of 235 
performance with highest viability after treatment being obtained with Me2SO/EG/glucose at 236 
a ratio of 4:2:1, followed by a combination of Me2SO/EG/methanol/glucose at a ratio of 237 
2:3:1:1 (Table 1). EG exhibited lower toxicity to AELC than Me2SO and PG when in 238 
combination with Me2SO. However, a solution of only EG and glucose (6:1), defined too 239 
viscous for LT (data not included in Table 1), exhibited significantly higher toxicity to AELC 240 
than the combination of EG, glucose and Me2SO with 50% versus 68% remaining viability 241 
(n=5 , p<0.01).  242 
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(iv) Vitrification properties of low toxic CPA solutions 243 
All five low toxicity solutions (Table 1 – solutions >90% viability (test 1)) vitrified (visual 244 
avoidance of ice formation) at a concentration of 70% (w/v), but only Me2SO and a 245 
combination of Me2SO/EG/Glucose in a ratio 5:1:1 vitrified (visual absence of ice) at 60% 246 
(w/v) (Figure 1). Those solutions that did not vitrify at 60% (w/v) contained 20% (w/v) or 247 
more EG. It was observed that ice disappearance during warming was slowest for a solution 248 
with Me2SO/EG/Glucose in a ratio of 4:2:1 (LTdeg), which was the only one that did not 249 
contain 10% (w/v) methanol. Increasing the overall CPA concentration proportionately to 250 
64% (w/v) was found to be consistent with avoidance of visible ice during warming with 251 
LTdeg.  252 
Standard small volume vitrification experiments were performed using the 5 CPA solutions 253 
of lowest toxicity and compared with the outcomes for toxicity testing without cryo-cooling 254 
at 0.5˚C. Recoveries of viability after 24h culture for vitrification experiments post thaw were 255 
very low using Me2SO alone (around 1%), whilst the best outcomes (53%) were seen with 256 
LTdeg (Table 1, Figure 1). From these range setting experiments, LTdeg was chosen to take 257 
forward into the full LT investigations.   258 
Liquidus Tracking experiments 259 
(i) Heat transfer measurements 260 
When the first LT runs were carried out, using Me2SO as a cryoprotectant, (with a freezer 261 
cooling rate of -1˚C/minute and a liquid volume of 450ml), the temperature of the sample 262 
inside the sample carrier was approximately 20˚C higher than the temperature of the Me2SO 263 
equilibrium melting point and 15˚C higher than the predicted target temperature. To increase 264 
the sample cooling rate by improving heat transfer, the freezer temperature was set up to 265 
10˚C below the predicted Me2SO liquidus curve. Although the CPA concentration inside the 266 
outlet tube and the sample carrier is comparable, the solution inside the insulated outlet tube 267 
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froze at sub-zero temperatures, as a result of its geometry and the resulting higher cooling 268 
rate. To avoid this, first infusions were carried out by operating the pumps manually, and the 269 
outlet was primed with 50% (w/v) CPA when not in use. This allowed the freezer 270 
temperature to be set on hold at -20˚C and to maintain the sample/concentration curve close 271 
to the liquids curve until a concentration of 25% (w/v) CPA at -8˚C was reached, before 272 
using inlet and outlet pump simultaneously (Figure 4). 273 
(ii) Machine delivered LT: Me2SO alone vs. new CPA solution 274 
Initial LT runs using the pump-driven mixing with a volume of 450ml (including 130ml of 275 
settled beads) using Me2SO as a single CPA resulted in no post-warming cell viability. When 276 
the newly developed CPA solution Me2SO/EG/Glucose (4:2:1) was used, cell viability was 277 
increased to 40% (+/- 7.7%) (n=3). 278 
(iii)  Inhomogeneous “cell per bead” survival 279 
It was noted in preliminary studies by using fluorescence microscopy that some of the beads 280 
contained a high proportion of viable cells, while others contained almost exclusively dead 281 
cells after re-warming from LT. It was assumed that the effect was caused by the temperature 282 
difference within the sample carrier (e.g. colder at the carrier wall, bottom or surface and 283 
warmer at the centre). Viability up to a CPA concentration of 35-40% (w/v), reached at a 284 
temperature of -15˚C, remained high and inhomogeneous AELC viability in beads was not 285 
observed. The inlet temperature was therefore maintained at -15˚C, while increasing the CPA 286 
concentration from 35 to 64% (w/v), to avoid any potential CPA toxicity effects related to 287 
temperature differences within the system. Nevertheless, strong variations in viabilities 288 
between individual beads were observed. It was suspected that stirring the entire sample 289 
volume was inefficient, resulting in regions of poor CPA mixing and therefore potential ice 290 
nucleation. 291 
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(iv)  The Liquidus Tracking stirrer 292 
To achieve more homogenous mixing conditions, the original Planer stirrer, designed to hold 293 
larger tissue constructs in the middle of the sample carrier while providing efficient CPA 294 
homogenisation, was replaced with a simple propeller stirrer. By using the new propeller 295 
stirrer, viabilities post LT were significantly improved from 38% +/-11.7 to 77% +/- 4.3 (n=4 296 
+/-SD) and strong variations in viable cell numbers between different individual beads were 297 
no longer observed (Figure 5).  298 
(v) Cell density impacts cell survival 299 
Alginate encapsulated spheroids (AES) of high cell densities (15x10
6
 cells/ml of beads) were 300 
less affected by LT treatment with new stirrer than AES of low cell density (4x10
6
 cells per 301 
ml/beads) with viabilities of 57% +/-9.7 and 11% +/- 6.9, respectively (n=17, p<0.01). Both 302 
cultures were processed within the same run. Beads of either type were easily distinguished 303 
under the microscope, which made it possible to take images of single beads and determine 304 
the viability using the established FDA/PI method.  305 
Although this procedure allowed testing of two populations of beads under exactly the same 306 
conditions, cell number and protein synthesis could not be determined because beads of 307 
different cell densities could not be physically separated. Thus, single run experiments were 308 
carried out with batches of either high or low cell density beads. Again higher cell density 309 
resulted in higher cell numbers, viability, albumin and alpha-fetoprotein production post LT 310 
cooling with respect to the positive control. For cell densities of 17x10
6 
and 20x10
6
 cells/ml 311 
of beads viability was 70% and 90%, viable cell numbers were 67% and 96% and albumin 312 
and alpha-fetoprotein release were 48% and 57%, and 80% and 88%, respectively (fraction of 313 
the untreated control after 48 hours of post warming – Figure 6). 314 
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Discussion 315 
Choice of CPA for LT 316 
We observed here that the pumps and stirrer of the semi-automated Liquidus Tracker are 317 
impaired above a viscosity of approximately 900 mPa·s (Me2SO at -40˚C). Thus, viscosity 318 
was identified as the first limiting factor for developing a new LT CPA solution. Dimethyl 319 
sulfoxide (Me2SO), ethylene glycol (EG) and propylene glycol (PG) were selected as 320 
penetrating CPAs based on their relatively low viscosity and their common use in 321 
vitrification protocols. Only four combinations (in increments of 10%) of Me2SO, EG and PG 322 
with 10% (w/v) glucose were of sufficiently low viscosity for our purpose. For this reason, 323 
viscosity was reduced by replacing 10% of a higher viscous penetrating CPA with methanol. 324 
Monovalent alcohols are not commonly used in cryopreservation protocols, mostly due to 325 
their known high toxic effects on many biological systems. However, methanol has been used 326 
successfully in fish semen and embryo preservation [24,25,42]. In these applications, the 327 
concentration used was 10% or less, which justified the concentration used here. Although of 328 
general high toxicity, methanol was well tolerated when combined with EG and low amounts 329 
(<=30% w/v) of Me2SO and due to its high permeability [5] might be considered useful for 330 
some vitrification protocols.  331 
Sugars are generally used to decrease the amount of penetrating CPAs while keeping similar 332 
final CPA concentrations and glass-forming tendencies. When testing different sugars for our 333 
LT CPA solutions, Me2SO was not replaced, but instead 10% (w/v) sugar was additionally 334 
included. The type of sugar used in our studies appeared to be irrelevant, which might 335 
suggest a general effect like reduced osmotic stress. It is known that sugars osmotically 336 
reduced the cell volume, and therefore triggering reduced uptake of penetrating CPA, which 337 
leads to less intracellular dehydration through CPAs and also reduced osmotic stress when 338 
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CPAs are washed out. However, we have previously shown that AELC maintain high 339 
viability after one-step addition and dilution of up to 40% (v/v) Me2SO when carried out at 340 
low temperatures [40]. The fact that AELC can support strong osmotic changes and that 341 
toxicity is generally and strongly decreased at low temperatures (osmotic  stress has been 342 
suggested  to increase at lower temperatures as the difference between transmembrane water 343 
fluxes and movement of penetrating CPA  increases [2]) might also indicate additional 344 
effects, such as cell membrane stabilization or even some sort of  biochemical toxicity 345 
neutralisation comparable to that reported for reduced toxicity of formamide through the 346 
addition of Me2SO [12]. For the semi-automated LT process osmotic stress is even further 347 
reduces as lower concentrated CPA solution is continuously added while being mixed by a 348 
stirrer. However, further work will be needed to assess the relevant importance of osmotic or 349 
chemical toxicities within the overall context of LT.    350 
Glucose was chosen for further LT studies for two reasons; firstly because it is clinically 351 
available and inexpensive and for automated LT large CPA volumes are needed and secondly 352 
because glucose has been reported to prevent irreversible binding of Me2SO to proteins [8]. 353 
EG is stated to be the least toxic CPA for hepatocyte virtification [23,30] but for AELC in 354 
LT, the combination of Me2SO (40% w/v) and EG (20% w/v) with 10% (w/v) glucose, 355 
resulted in significantly higher viability than either of the CPAs on its own with 10% (w/v) 356 
glucose. This observation corresponds to previous findings from other authors in 357 
chondrocytes and alginate encapsulated HepG2 and β-TC-cells, which suggest that 358 
combinations of penetrating CPAs are less toxic than the use of a single CPA [20,26,46]. We 359 
could find no explanation for the interaction between EG and Me2SO, but both solutions are 360 
also main components of the well-known and commercially available vitrification solutions 361 
VS55 and M22 [12,14]. A similar composition of 22% EG and 18% Me2SO and 17.5% for 362 
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both EG and Me2SO have also shown good results for the vitrification of cumulus cells [41] 363 
and equine embryos, respectively [35]. It is interesting, that – although developed to be first 364 
of low viscosity and second of low toxicity – our final chosen LT solution for AELC 365 
resembled those that are already commercially sold for other standard vitrification protocols. 366 
We speculate that viscosity plays an important role in realizing an optimum between CPA 367 
penetration and dehydration. 368 
When developing new CPA mixtures, it is necessary to assess toxicity of cryoprotectants at 369 
the concentrations needed to vitrify. To get an estimation of the vitrification properties of the 370 
potential CPA solutions, Me2SO and the five CPA solutions of lowest toxicity to AELC were 371 
vitrified in small volumes and CPA solutions (without AELC) and were optically compared 372 
for ice formation. Optical assessment of vitrification is only a semi-quantitative method 373 
compared to other physical measurements such as DSC, but it has been used in other studies 374 
[18,50]as a direct method which can allow multiple conditions to be investigated at the same 375 
time. Whilst all solutions vitrified at 70% (w/v) CPA, only Me2SO and the mixture of 376 
Me2SO/EG/glucose with a ratio of 5:1:1 vitrified at 60% (w/v) final CPA. One probable 377 
explanation why the other four solutions did not vitrify is the higher concentration of EG and 378 
methanol. EG has been described as a less effective vitrifier than Me2SO and PG [3] and 379 
methanol only vitrifies on its own under high pressure [6]. However, methanol seemed to 380 
have increased the rate at which ice melts during the warming phase, which could be 381 
advantageous for decreasing the amount of potential devitrification.  382 
The top five low toxicity CPA solutions used to manually vitrify AELC in small volumes 383 
performed generally in the same order as they did in the toxicity studies. Reduced incubation 384 
time before plunging AELC into liquid nitrogen could be beneficial for solutions with higher 385 
concentrations of fast penetrating CPAs (Me2SO, methanol), and some solutions might vitrify 386 
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at lower concentrations which would reduce CPA toxicity and increase viability. For the 387 
chosen set-up the solution of lowest toxicity was superior to the other solutions and proved to 388 
be an efficient vitrifier in the small volume protocol.  389 
Final CPA concentrations for LT are of less risk for toxicity than for conventional 390 
vitrification, as they are reached at very low temperatures (<-30˚C), at which CPA 391 
penetration and toxicity are suspected to be strongly reduced. However, at higher 392 
temperatures CPA toxicity is to be crucial for cell survival during the LT process. This would 393 
point to choosing the lowest toxicity CPA mixture instead of the best vitrifier for AELC 394 
preservation by LT.  395 
The semi-automated machine-delivered LT process 396 
Although LT allows for much slower cooling rates than conventional vitrification, cooling 397 
rates can be still too slow in respect of practicality when large volumes are being cooled. In 398 
our system heat is transferred in two ways: conduction and convection. As the inlet is led 399 
through a tube of several meters that is kept within the freezer chamber, the temperature of 400 
the inlet solution was found to match that of the freezer chamber at the moment of addition. 401 
The shape of the LT sample carrier (small surface area to volume ratio) is unfavourable for 402 
fast cooling and warming rates by conduction. When the temperature difference between the 403 
freezer chamber and sample is small, both conduction and convection have consequently 404 
little impact on the overall sample temperature. Moreover, first CPA addition steps only 405 
require small amounts of highly concentrated CPA solution to increase the sample 406 
concentration. Thus, the initial temperature change by convection can be neglected. For our 407 
work, neither sample volume nor the geometry of the sample carrier could be changed. 408 
However reducing the freezer temperature from 5˚C above to 20˚C below the predicted 409 
liquidus curve helped to increase the sample cooling rate, although the risk of outlet tube 410 
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freezing had to be resolved. Using more inlet volume of lower concentrated CPA, thus 411 
increasing convection, can further be used to increase the cooling rate but is logistically more 412 
challenging. This type of approach for LT could be described as semi-automatic; the pumps 413 
had to be operated by manual control to balance the relative volume exchanges as described; 414 
however, the pumps allowed better overall control of solution movement than could be 415 
achieved for example by manual decanting.   416 
No viability of AELC was detected when Me2SO was used for semi-automated LT, but was 417 
increased to approximately 40% viability when Me2SO was replaced with the newly 418 
developed CPA solution, suggesting that CPA toxicity and/or osmotic injury was not fully 419 
suppressed by the LT process. Inhomogeneous distribution of viable and dead cells between 420 
alginate beads led to the assumption that temperature differences within the LT system had 421 
caused this effect. The inlet temperature during the cooling process is much colder than the 422 
sample temperature and there is also a temperature gradient across the sample carrier with 423 
lower temperatures at the outside and higher temperatures on the inside of the sample 424 
container. Inhomogeneous distribution of viable and dead cells was not noted for CPA 425 
concentrations below 35% (w/v), normally reached at -15˚C. Consequently, the inlet and 426 
sample solution temperature were maintained at -15˚C, thus offsetting the temperature 427 
difference inside the sample carrier, while the sample CPA concentration was increased to 428 
64% (w/v). However, strong variations in the number of viable cells per bead were still 429 
detected, excluding temperature as the main factor for CPA toxicity. 430 
Another possibility was that the method of stirring was the cause of this effect. The original 431 
Planer stirrer was designed to operate alongside the sample carrier wall to avoid any 432 
interference with larger, static constructs in the middle of the sample carrier. However, this 433 
design exhibits strong differences across the sample carrier in respect to mixing behaviour. 434 
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For example, AELC trapped between the static pedals and the moving part of the stirrer are 435 
subject to stronger mixing and higher shear forces than AELC that are located at the centre of 436 
sample carrier. To overcome these mixing differences a propeller stirrer was designed. As a 437 
result viabilities were increased to around 80% and viable and non-viable cells were evenly 438 
distributed across alginate beads. The inlet port being in close proximity to the Planer stirring 439 
system is consistent with the theory that AELC located in the “intense mixing zone” and 440 
close to the inlet of highly concentrated CPA, experienced high intra- and extracellular CPA 441 
concentration differences and an enhanced mass transport across membranes as a result of 442 
high kinetic energy caused by intensive stirring. Thus, chemical toxicity [12], dehydration 443 
and osmotic stress [44] may have been reinforced through vicious mixing with this system, 444 
which were improved by use of the propeller stirrer. 445 
An interesting effect was seen when beads of varying cell densities were used for LT. Low 446 
cell density beads tested in the same experiment, and therefore undergoing exactly the same 447 
procedure as did high cell density beads, showed significantly reduced cell survival post 448 
recovery. To measure cell numbers and protein release exclusively, experiments with beads 449 
of the two different cell densities had to be independently repeated, but the outcomes were 450 
the same. 3D cell cultures of higher cell density showed higher post-warming viability, cell 451 
number and protein release. This is in accordance with previous observations: Higher cell 452 
recovery of hepatocyte spheroids in comparison to single cell suspension following 453 
cryopreservation has been reported by Lee and colleagues [27] and vitrification studies with 454 
primary rat hepatocytes by Magalhães have shown better post-cryopreservation viability for 455 
tissue-like culture than for single cells. They concluded that cell-to-cell contact is beneficial 456 
in the maintenance of viability [29]. This might be due to higher cell activity in 3-D cell 457 
cultures [37, 38], which has been linked to higher cell recovery following cryopreservation in 458 
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single cell suspension [7]. It should be pointed out that the BAL system would require high 459 
cell density (i.e. high total cell numbers) beads for clinical application [43].   460 
In respect of shear forces created by the stirrer during LT, it can be expected that higher cell 461 
density is beneficial, as the outer cells may provide protection to those located closer to the 462 
centre. This also applies in respect of excessive dehydration. In 3-dimensional cell constructs, 463 
water diffuses sequentially from one cell to its neighbour. Cells in the surface layer respond 464 
to osmotic changes in the extracellular medium; interior cells respond only to osmotic 465 
changes in cells of surfaces, and thus are exposed to slower rates of dehydration [28]. Shear 466 
stress is also likely to cause cell death by membrane disruption [36] and would account for a 467 
more homogenous distribution of viable and dead cells amongst beads when the propeller 468 
stirrer was used. However, with the current LT set up, shear stress would not seem to be a 469 
major injurious factor.   470 
To further improve the LT system, it would be highly advantageous if the intracellular CPA 471 
and water concentration over the LT process could be monitored. For example, if it can be 472 
shown that CPA toxicity is negligible once CPA and water flux are (nearly) reversed and in 473 
the case that this happens within the temperatures range (0 to -40˚C) of CPA addition and 474 
reduction, LT protocols could be suitably adapted. The CPA concentration could then be 475 
increased at a higher temperature to ensure intracellular vitrification before cooling the 476 
sample. Once reached, the concentration needed to prevent devitrification during warming 477 
could be manipulated, for example, by using ice blocking agents [49] to minimise the risk of 478 
unwanted ice nucleation. 479 
Conclusion 480 
This work has shown that it is possible to use LT to vitrify large volumes of cell therapies 481 
such as AELC in the 3-D format. Further improvements to equipment technology, especially 482 
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in respect to more automatization are required. An optimized stirring and CPA inlet system, 483 
as well as the use of 3D cultures of higher cell density (>20x10
6 
cells/ml beads) may further 484 
increase post-warming viability and performance in the future. In theory, the LT volume 485 
could be further up-scaled by engineering a larger cell chamber with a scaled stirrer system.  486 
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 632 
Optical vitrification study:
(4ml of 60 or 70% (w/v) CPA 
w/o AELC in 12-well plates)
Viscosity study : select CPA solution comparable in 
viscosity to Me2SO at -40C (10ml 70% (w/v) CPA w/o 
AELC in 15ml Centrifuge tubes)
CPA toxicity study 
(0.25ml AELC in 15ml Centrifuge tubes, 60% (w/v) CPA)
Study 1: 10min. at 0.5C
12 low viscous CPA solutions
5 lowest toxic CPA solutions
Toxicity study 2: 
20min. at 0.5C
Small scale vitrifiction (0.25ml 
AELC in 2ml Cryovials, 63% 
(w/v) CPA)
lowest toxicity: Me2SO/EG/glucose (ratio: 4/2/1) used for automated 
Liquidus Tracking (450ml, 64% (w/v) final CPA concentration)  633 
 634 
Figure 1: CPA development 635 
 636 
Step 1: compare viscosity of combinations of Me2SO, EG, PG, glucose (in increments of 10% (w/v)) and 637 
methanol (10% (w/v)) to Me2SO alone at -40˚C. Select combinations with similar viscosity to Me2SO. Step 638 
2: test toxicity of low viscous CPA solutions on AELC (10 minutes at 0.5˚C). Step 3: repeat step 3 for 5 639 
lowest toxic CPA solutions for 20 minutes. Step 4: test 5 lowest toxic CPA solutions in a standard small 640 
scale vitrification process. Step 6: visual observation of vitrification properties of 5 low toxic CPA 641 
solution. Step 1-6: Incubation time and volumes were optimized for each test. 642 
 643 
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 644 
 645 
 646 
Figure 2: The LT cooling and warming profile  647 
Temperature profile of the LT sample and the freezer were assessed by thermocouples being placed 648 
inside the sample (blue line), and inside the freezer chamber (red line). When the sample reached a 649 
temperature of -95˚C during warming, the sample container was placed outside the freezer at room 650 
temperature (indicated by the interrupted red line at 200 minutes when the chamber was opened) for fast 651 
initial warming to achieve a core sample temperature of -40˚C. The freezer chamber temperature was 652 
also set at -40˚C, and the sample was returned to the chamber for the reverse LT process. To increase the 653 
sample temperature further, the freezer temperature was set manually from initially -25˚C to -20˚C then -654 
15˚C and finally -10˚C, to keep the sample temperature above its liquidus curve and prevent freezing. 655 
 656 
 657 
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 661 
Figure 3: Sugars and sugar combination as non-penetrating CPA — effect in cell viability 662 
AELC (0.25ml) were incubated in 50% (w/v) Me2SO (white) or 50% (w/v) Me2SO plus 10% (w/v) sugar, 663 
either of one single sugar (grey) or two different sugars (light grey). AELC were incubated for 10 minutes 664 
at 0.5˚C, using a step-wise CPA addition and reduction procedure. AELC were cultured for 24 hours in 665 
complete media at 37˚C before measuring viability by FDA/PI staining. Data were n=5 +/- SD. Viability 666 
obtained with 50% (w/v) Me2SO was significantly lower than with solutions containing sugar, 667 
***p<0.001.  668 
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 669 
 670 
Figure 4: Freezer and sample cooling profile relative to the liquidus curve 671 
Solutions with CPA concentrations below the liquidus curve (red) freeze, while those above remain liquid. 672 
Liquidus Tracking: by keeping the sample temperature and CPA concentration just above the liquidus 673 
curve, CPA toxicity was reduced and ice nucleation avoided. Freezer cooling profile 1 resulted in a 674 
discrepancy of ˜15˚C of the obtained sample profile (profile 1) to the expected profile (not shown) and was 675 
approximately 20˚C higher than the liquidus curve. To increase the sample cooling rate (sample profile 2) 676 
the freezer temperature (freezer profile 2) was initially set to -20˚C below the liquids curve. 677 
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 679 
Figure 5: Planer stirrer versus propeller stirrer 680 
A1: Planer stirrer — the paddles of the upper part move between the sample carrier wall and the paddles 681 
of the bottom part - possibly creating strong differences in mixing behaviour and shear forces between 682 
the sample carrier centre and on the outside. A2: Propeller stirrer — used for more homogenous mixing. 683 
B1: AELC viability after using the Planer stirrer. B2: Propeller stirrer — viability was significantly 684 
increased and bead to bead viability variation was reduced. The figure shows phase images, and images of 685 
live (green, stained with FDA) and dead (red, stained with PI) cells.  686 
 687 
  688 
 689 
Note: Figure 5- please print in color 690 
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 694 
Figure 6: Impact of low and high cell densities on cell recovery 695 
The higher the cell density was before the LT process (4, 7, 9, 17, 20 million cells/ml of beads), the higher 696 
was the post-warming viability, viable cell number, albumin and alpha-fetoprotein synthesis. For each 697 
cell density one LT run was performed. Viability, cell number and protein production were measured in 5 698 
replicates for each sample, and shown as means +/- SE .  130ml of beads in 450ml CPA were used. 699 
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